Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 541 participants.
Also called NCT06027307
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 541 participants
- Registry
-
NCT06027307
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06027307. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-25 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
- Acronym
- EVENT
- Condition
- Tricuspid Regurgitation
- Intervention (Drug)
- Enavogliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Asan Medical Center
- Collaborator
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct06027307- Content hash
3d35487008503a41f11e6f550e76ac68a78daf577f8e30f943febecd6f9588d1